Abbott Cuts Full-Year Outlook, Citing Mild Flu Season and Acquisition Impact
Summary
Abbott Laboratories has cut its full-year adjusted earnings outlook to a range of $5.38-$5.58 per share, down from its prior guidance of $5.55-$5.80. This reduction is primarily attributed to a 20-cent per share dilutive impact from the recently completed Exact Sciences acquisition and weaker-than-expected first-quarter diagnostic sales due to a mild flu season. While earlier reports today mentioned updated guidance, this headline provides the critical detail that the update is a significant cut, offering specific reasons for the revised outlook. This is a material negative development for a large-cap company, especially with the stock trading near its 52-week low. Investors will closely watch the integration of Exact Sciences and the performance of diagnostic sales in upcoming quarters, particularly the impact of future respiratory seasons.
At the time of this announcement, ABT was trading at $96.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $168.8B. The 52-week trading range was $96.37 to $139.06. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.